论文部分内容阅读
在挪威,对致死性药物不良反应的报告已成为医务工作者的法定义务.尽管如此,漏报情况仍可能大量存在.据了解,挪威自报系统每年收到的1100份病例报告中,仅60—80份为致死性药物不良反应报告,因而,了解致死性药物不良反应的实际发生率已成为一个重要问题.为了获得药物相关性死亡发生率的初步估计资料,作者在挪威人群中进行了一次小规模的前瞻性研究以评估药物相关性死亡的漏报率并决定是否开展持续时间更长和更有决定意义的大规模研究.以一所有500张病床县医院的全部住院病人为研究对象,从病人入院开始便收集药物应用的详细信息,并选择部分病例进行专门的药物分析,由临床药理学、内科学、病理学及药学方面的专家对所获得的信息,包括尸检资料进行评估.评估因果关
In Norway, reports of fatal adverse drug reactions have become statutory obligations of medical workers, however, and the omission may still be substantial.It is understood that the Norwegian self-reported system receives 1,100 case reports each year, only 60 -80 reports of fatal adverse drug reactions, and therefore, understanding the actual incidence of fatal adverse drug reactions has become an important issue. In order to obtain preliminary estimates of the incidence of drug-related deaths, the authors conducted one in the Norwegian population Small-scale prospective study to assess the omission rate of drug-related deaths and to decide whether to conduct larger and more deterministic longer-term studies.With all inpatients in a county-level 500-bed hospital as study subjects, Detailed information on drug use is collected from the time of admission to the patient and some cases are selected for specific drug analysis and the information obtained, including autopsy data, is evaluated by experts in clinical pharmacology, internal medicine, pathology and pharmacy. Causal off